Insight Molecular Diagnostics (IMDX) Change in Accured Expenses (2015 - 2026)

Insight Molecular Diagnostics has reported Change in Accured Expenses for 12 years, with the latest figure at -$105000.0 in Q1 2026.

• Quarterly Change in Accured Expenses fell 110.22% year-over-year to -$105000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 32.81% YoY) and the FY2025 annual result came in at $2.6 million, up 173.63% from the prior year.
• Change in Accured Expenses retreated to -$105000.0 in Q1 2026 per IMDX's latest filing, from $3.6 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $3.6 million in Q4 2025 and troughed at -$3.1 million in Q2 2025.
• A 5-year average of -$56000.0 and a median of $126000.0 in 2023 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses slumped 12576.19% in 2023, then surged 415.08% in 2024.
• Over 5 years, Change in Accured Expenses stood at -$125000.0 in 2022, then sank by 351.2% to -$564000.0 in 2023, then surged by 224.82% to $704000.0 in 2024, then jumped by 404.97% to $3.6 million in 2025, then plunged by 102.95% to -$105000.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$105000.0, $3.6 million, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.